208 results about "Sulfated glycosaminoglycan" patented technology

The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

The invention relates to compositions and methods for the modulation of the permeability of the epithelial cell barrier complex. In particular, the invention provides compositions and methods for using polysaccharides, preferably glycosaminoglycans, and agents that modify cell surface glycosaminoglycans, preferably glycosaminoglycan-degrading enzymes to modulate intercellular junctions. The compositions and methods provided can be used to facilitate the delivery of biologically active molecules.

The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia / thrombosis (HIT / HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4 / heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT / HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.

The invention relates, in part, to methods and compositions for the intracellular delivery of polysaccharides. In particular, the methods and compositions relate to the intracellular delivery of glycosaminoglycans, such as heparin. The invention in other aspects relates to the use of glycosaminoglycans for the treatment of proliferative disorders, such as cancer. The invention is still other aspects relates to improving cell viability. The invention also relates to the delivery of polysaccharides while avoiding unwanted effects of the polysaccharides. For example, heparin can be delivered while avoiding its anticoagulant effects.

The invention relates to methods and products for characterizing and using polysaccharides. Low molecular weight heparin products and methods of use are described. Methods for characterizing purity and activity of polysaccharide preparations including glycosaminoglycans such as heparin are also described.

The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

The invention relates to methods and products for characterizing and using polysaccharides. Low molecular weight heparin products and methods of use are described. Methods for characterizing purity and activity of polysaccharide preparations including glycosaminoglycans such as heparin are also described.

The invention relates to the immobilization of polysaccharides on a substrate. In particular, the invention relates to biologically active surfaces formed by the immobilization of glycosaminoglycans on a substrate. The invention also provides biologically active surfaces that contain one or more different glycosaminoglycans and, optionally, one or more other agents. These agents can be biological or therapeutic agents. The invention also relates to methods of using the surfaces of the invention, such as, methods of affecting biological processes, eliciting patterns of cellular response, screening, treatment, diagnosis and preventing food contamination and / or spoilage.

A method of managing a patient having an accumulation of mucoid, mucopurulent or purulent material containing glycosaminoglycans, the method comprising the step of administering at least one glycosaminoglycans degrading enzyme to the patient in an amount therapeutically effective to reduce at least one of the following: the visco-elasticity of the material, pathogens infectivity and inflammation. An article of manufacture comprising an inhaler including, as an active ingredient, at least one glycosaminoglycans degrading enzyme for generating aerosols including the enzyme for management a patient having an accumulation of mucoid, mucopurulent or purulent material containing glycosaminoglycans.

This invention relates, in part, to methods and compositions that modulate the stem cell environment. More specifically, the invention relates, in part, to methods and compositions for modulating stem cell differentiation. Such modulation, in some aspects of the invention, is accomplished by agents that modulate glycosaminoglycans in the stem cell microenvironment (i.e., at or on the cell surface and / or in the extracellular matrix). Therefore, methods and compositions are provide for modulating glycosaminoglycan moieties, e.g., heparan sulfate glycosaminoglycan (HSGAG) moieties, in the microenvironment of stem cells. Methods and compositions for promoting or inhibiting embryonic stem cell differentiation (e.g., differentiation into endothelial cells) are also provided. This invention also relates, therefore, in part, to cell populations (e.g., endothelial cell populations or impoverished endothelial cell populations) that can be produced with the methods and compositions provided. Furthermore, the invention relates, in part, to tissues, and uses thereof, formed by the methods and compositions provided. Moreover, the invention also relates, in part, to methods of treatment using the methods and compositions provided.

An endovascular device for occluding a vascular aneurysm is disclosed. The device includes a polymeric shell member that, in one embodiment, may be constructed from a bioactive and biocompatible polyurethane-diol-glycosaminoglycan copolymer, and a biocompatible metallic frame member. The copolymer is sufficiently flexible and strong for endovascular delivery into a vascular aneurysm and for use as a polymeric shell for receiving the biocompatible metallic frame member. The biometallic frame member may include one or more components constructed from a NiTi alloy.

Transluminal drug delivery method and device embodiments can include a urethral suppository formulated to prevent or treat diseases of the urethra and surrounding organs, such as interstitial cystitis or urethritis, by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense mechanisms of these tissues. Adverse effects on the glycosaminoglycan (GAG) barrier can be mitigated or eliminated by the presence of a suitable polysaccharide in the suppository.

The present invention features automated devices, kits, and assay methods for measuring glycosaminoglycan levels in body fluids such as urinary glycosaminoglycan excretion or blood heparin levels. Such devices, kits and methods are useful, e.g., for monitoring heparin therapy or diagnosing or monitoring mucopolysaccharidoses.

C-glycoside compounds are suited for stimulating the synthesis of glycosaminoglycans containing a D-glucosamine and / or N-acetyl-D-glucosamine residue, advantageously hyaluronic acid, and / or proteoglycans, advantageously proteoglycans containing hyaluronic acid, by fibroblasts and / or keratinocytes.

The present invention relates to porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents, and methods of producing such matrices. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified plasma proteins, thus obviating the need for exogenous anti-fibrinolytic agents. Furthermore, incorporation of glycosaminoglycans and bioactive agents during the formation of the matrix results in a sponge having advantageous biological, mechanical and physical properties. The compositions of the present invention are useful clinically, per se or as cell-bearing implants.

Compositions and methods relating to partially hydrolyzed fucoidan for use in dietary supplements and skin-care products are described. Fucoidan from brown seaweeds is partially hydrolyzed and / or sulfonated and then mixed with other ingredients for use as a dietary supplement in beverage, capsule, or tablet form or for use as a skin-care product. Other ingredients that can be included in the dietary supplements include vitamins, minerals, amino acids, carotenoids, flavonoids, antioxidants, aminosugars, glycosaminoglycans, and botanicals. Skin care products according to the present invention comprise partially hydrolyzed fucoidan and a base.

The intervertebral disc contains no blood vessels. Nutrients and waste are diffused mainly through adjacent vertebral bodies. As we age, calcified layers form between the disc and vertebral bodies, blocking diffusion. The disc begins to starve and flatten. The weight shifts abnormally from disc to the facet joints causing strain and back pain. Under anaerobic conditions, lactic acid is produced causing acidic irritation and unspecific pain. A U-shaped disc shunt is delivered into and sealed within the degenerated disc simply by needle puncturing and withdrawal, to draw nutrients from bodily circulation into the avascular disc. A continual supply of nutrients increases biosynthesis of the water-retaining sulfated glycosaminoglycans, hence swelling pressure within the disc. The weight is re-shifted from the facet joints to the regenerated disc, alleviating back pain. With oxygen transported through the shunt, anaerobic production of lactic acid is minimized. In addition, the residual lactic acid is expelled through the U-shaped shunt during disc compression into bodily circulation to alleviate unspecific pain.

An object of the present invention is to provide a preventing agent or a treating agent for arthritis or to provide foods and drinks, additives for foods and drinks, feeds or additives for feeds for prevention or treatment of arthritis. In order to achieve the above object, the present invention provides a preventing or treating agent for arthritis or foods and drinks, additives for foods and drinks, feeds or additives for feeds for prevention or treatment of arthritis comprising plant belonging to the genus Hydrangea or an extract of the plant and amino sugar or a salt thereof and / or glycosaminoglycan or a salt thereof as active ingredients.

A lip balm product having a synthetic ceramide, an anti-irritant compound, sodium hyaluronate, cosmetic wax, boswellic acids and / or esters and / or salts thereof, extract of the Portuluca pilosa plant, matrikin-mimetic peptide, dehydrated microspheres of marine collagen and glycosaminoglycans, and mica along with optional lip balm formulation acceptable carriers and / or solvents. Where desired, the lip balm may further contain medicinal agents suitable for the treatment of various conditions of the lip.

An implantable biodegradable porous fibrous matrix is disclosed, the fibrous matrix being constructed of fibers arranged in a nonwoven array. The density of the nonwoven array is adjusted in the manufacturing process to obtain an optimum density of the array for tissue ingrowth. When implanted, the optimum density fibrous matrix provides for a superior biological response of the host in terms of tissue growth, especially for tissues containing glycosaminoglycans (GAGs). The optimum density fibrous matrix is therefore provided with properties useful in repair and / or regeneration of mammalian tissue.

The present invention provides composition comprising one or more glycosaminoglycan mimetics and uses thereof. The subject glycosaminoglycan mimetics are particularly useful for treatment of neuronal injuries including without limitation spinal cord injuries.

The invention relates to the discovery of a novel Chondroitinase Glycoproteins (CHASEGP's), methods of manufacture, and potential uses in conditions where removal of chondroitin sulfates may be of therapeutic benefit. Chondroitinase Glycoproteins require both a substantial portion of the catalytic domain of the CHASEGP polypeptide and asparagine-linked glycosylation for optimal chondroitinase activity. The invention also includes carboxy-terminal deletion variants of CHASEGP that result in secreted variants of the protein to facilitate manufacture of a recombinant CHASEGP. Further described are suitable formulations of a substantially purified recombinant CHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. CHASEGP is useful for the degradation of glycosaminoglycans and chondroitin sulfate proteoglycans under clinical conditions where their removal is of therapeutic value.

Partially desulphated glycosaminoglycan derivatives are described, particularly heparin, and more particularly a compound of formula (I) where the U, R and R1 groups have the meanings indicated in the description. These glycosaminoglycan derivatives have antiangiogenic and heparanase-inhibiting activity and are devoid of anticoagulant activity.

The present invention relates to a water treatment agent and a preparation method thereof, wherein the water treatment agent comprises, by weight, 20-30 parts of diatomaceous earth, 15-18 parts of nanoparticles with biological enzyme immobilized on the surface, 3-5 parts of graphene, 30-45 parts of perlite, 30-45 parts of vermiculite, and 10-15 parts of glycosaminoglycan. The preparation method comprises: preparing nanoparticles with biological enzyme immobilized on the surface, and then preparing the water treatment agent. According to the present invention, the water treatment agent has characteristics of good treatment effect, no pathogenicity, safety, biodegradability, environmental protection, wide raw material source, and low production cost, can be used in the fields of papermaking wastewater, heavy metal wastewater, urban sewage, food processing and fermentation industries, and the like, and has wide applicability.

Disclosed are neocartilage compositions characterized by having multiple layers of cells, said cells being surrounded by a substantially continuous insoluble glycosaminoglycan and collagen-enriched hyaline extra-cellular matrix, and which neocartilage phospholipids are advantageously enriched in anti-inflammatory n-9 fatty acids, particularly 20:3 n-9 eicosatrienoic or Mead acid.Also disclosed are methods of growing neocartilage in substantially serum-free growth media and methods of producing a conditioned growth media containing compounds effective to enhance neocartilage formation.The neocartilage compositions are useful as implants and as replacement tissue for damaged or defective cartilage and as a model system for studying articular cartilage disease and response to natural and synthetic compounds.

The present invention provides peptide derivatives with a specific affinity for glycosaminoglycan molecules. These peptide derivatives include multimers as well as chemically modified peptides and may be prepared by a variety of methods. The peptides of the invention have numerous functions, including but not limited to use as inhibitors of glycosaminoglycan-mediated signaling events and targeting agents. Peptides of the invention may be directed against any glycosaminoglycan, including hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C, dermatan sulfate, heparin, keratan sulfate, keratosulfate, chitin, chitosan 1, and chitosan 2. The peptide derivatives of the invention also have therapeutic uses in the treatment and prevention of diseases involving inflammatory diseases, cancer, and cancer metastasis, autoimmune diseases, etc.

In one embodiment, a composition containing ergothioneine and / or synthesized l-ergothioneine and one or more compounds selected from the group consisting of vitamin B-12, glucosamine sulfate, calcium ascorbate, turmeric extract, black pepper extract, hyaluronic acid, collagen, glycosaminoglycans, cat's claw extract, acai berry; and white willow bark extract is provided to a mammal to improve a variety of health related factors, including but not limited to brain health, joint health, eye health, mitondchorial optimization / improvement and reduction of inflammation and pain in a mammal.

The invention discloses a compound growth factor collagen sustained-release carrier material for promoting repair of various traumas in oral and maxillofacial regions and a method for preparing the same. In order to overcome the defect of poor curative effect existing in the conventional medicaments for treating the traumas of various tissues such as an oral cavity and a face, a bioactive collagen sustained-release material is prepared by combining collagen modified by liposome, chitosan, glycosaminoglycan and the like with one or more of a basic fibroblast growth factor (bFGF), a platelet derived growth factor (PDGF-BB), a vascular endothelial growth factor (VEGF) and a keratinocyte growth factor (KGF). The bioactive collagen sustained-release material is characterized in that: each gram of bioactive collagen sustained-release material contains not less than 10ng of growth factors, and the bioactive collagen sustained-release material has the obvious effect of treating various facial tissue traumas such as tooth extraction wound, oral ulcer, facial nerve injury, mandibular defect and the like. The collagen sustained-release carrier material can continuously release an effective amount of the growth factors to the wound for a long time, fully exert the inducing effect of the growth factors and obviously shorten the time for wound healing so as to fulfill the aim of treatment.

The present invention relates to novel C-glycoside compounds of given absolute configuration, to a process for synthesising them and to compositions containing them. The invention also relates to the cosmetic use of these C-glycoside compounds as agents to stimulate the synthesis of glycosaminoglycans containing a D-glucosamine and / or N-acetyl-D-glucosamine residue, advantageously hyaluronic acid, and / or of proteoglycans, advantageously proteoglycans containing hyaluronic acid, by fibroblasts and / or keratinocytes. The invention also relates to a cosmetic process for treating keratin materials using a composition containing at least one C-glycoside compound according to the invention.